

Cited in: *EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

Original Research Articles

- Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer**
S.Y. Park, G.E. Byun, C.Y. Lee, J.G. Lee, D.J. Kim, H.C. Paik, K.Y. Chung (Republic of Korea) 1
- Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer**
B.J. Ager, S.M. Wells, J.D. Gruhl, G.J. Stoddard, R. Tao, K.E. Kokeny, Y.J. Hitchcock (USA) 6
- ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib**
E. Thunnissen, B.I. Lissenberg-Witte, M.M. van den Heuvel, K. Monkhorst (the Netherlands), B.G. Skov, J.B. Sørensen, A. Mellemaard (Denmark), A.M.C. Dingemans, E.J.M. Speel, A.J. de Langen, S.M.S. Hashemi, I. Bahce, M.A. van der Drift, M.G. Looijen-Salamon (the Netherlands), J. Gosney, P.E. Postmus (United Kingdom), S.M.S. Samii (the Netherlands), F. Duplaquet, B. Weynand (Belgium), X. Durando, F. Penault-Llorca (France), S. Finn, A.O. Grady (Ireland), B. Oz, N. Akyurek (Turkey), R. Buettner, J. Wolf (Germany), L. Bubendorf (Switzerland), S. Duin (the Netherlands), I. Marondel, L.C. Heukamp (Germany), W. Timens, E.M.D. Schuurin (the Netherlands), P. Pauwels (Belgium), E.F. Smit (the Netherlands) 13
- Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system)**
G. Stamatis, G. Leschber, B. Schwarz, D.L. Brintrup, C. Ose, G. Weinreich, B. Passlick, E. Hecker, C. Kugler, H. Dienemann, T. Krbeek, S. Eggeing, R. Hatz (Germany), M.R. Müller (Austria), W. Weder (Switzerland), C. Aigner, K.-H. Jöckel (Germany) 19
- Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience**
M. Chiappetta, E. Zanfrini, L. Giraldo, M.G. Mastromarino, L. Petracca-Ciavarella, D. Nachira, M.T. Congedo, V. Aprile, M.C. Ambrogi, M. Lucchi, P.L. Filosso, E. Ruffini, F. Guerrera, A. Mulè, G. Ali, L. Molinaro, F. Lococo, E. Meacci, S. Margaritora (Italy) 27
- Non-small cell lung cancer with loss of expression of the SWI/SNF complex is associated with aggressive clinicopathological features, PD-L1-positive status, and high tumor mutation burden**
T. Naito, H. Udagawa, S. Umemura, T. Sakai, Y. Zenke, K. Kirita, S. Matsumoto, K. Yoh, S. Niho, M. Tsuboi, G. Ishii, K. Goto (Japan) 35
- Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options**
P. Jurmeister, C. Vollbrecht, A. Behnke, N. Frost, A. Arnold, D. Treue, J.-C. Rückert, J. Neudecker, L. Schweizer, F. Klauschen, D. Horst, M. Hummel, M. Dietel, M. von Laffert (Germany) 43
- Effects of different brain surveillance strategies on outcomes for patients with EGFR-mutant metastatic lung adenocarcinoma under targeted therapy**
C.-I. Shen, H.-C. Huang, C.-L. Chiang, Y.-H. Luo, T.-H. Shiao, C.-H. Chiu (Taiwan) 52
- Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy**
Y. Ikematsu, K. Tanaka, T. Yanagihara, R. Liu, H. Inoue, Y. Yoneshima, K. Ota, E. Iwama, S. Takata, K. Hata, Y. Takahata, H. Wataya, Y. Nakanishi, I. Okamoto (Japan) 58

(Contents continued overleaf)



A prospective phase II study of carboplatin and <i>nab</i>-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)	
H. Asahina, S. Oizumi, K. Takamura, T. Harada, M. Harada, H. Yokouchi, K. Kanazawa, Y. Fujita, T. Kojima, F. Sugaya, H. Tanaka, R. Honda, E. Kikuchi, T. Ikari, T. Ogi, K. Shimizu, M. Suzuki, S. Konno, H. Dosaka-Akita, H. Isobe, M. Nishimura (Japan)	65
Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors	
D. Puliti, M. Mascalchi, F.M. Carozzi, L. Carrozzi, F. Falaschi, E. Paci, A. Lopes Pegna, F. Aquilini, A. Barchielli, M. Bartolucci, M. Grazzini, G. Picozzi, F. Pistelli, A. Rosselli, M. Zappa (Italy)	72
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with <i>ALK</i>-positive non-small-cell lung cancer	
M. Pérol (France), N. Pavlakis (Australia), E. Levchenko (Russia), M. Platania (Italy), J. Oliveira (Portugal), S. Novello, R. Chiari (Italy), T. Moran (Spain), E. Mitry, E. Nüesch, T. Liu, B. Balas (Switzerland), K. Konopa (Poland), S. Peters (Switzerland)	79
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater	
L. She, H. Hu, M. Liao, X. Xia, Y. Shi, L. Yao, D. Ding, Y. Zhu, S. Zeng, L. Shen, J. Huang (China), D.P. Carbone (USA)	88
Prognostic relevance of regional lymph-node distribution in patients with N1-positive non-small cell lung cancer: A retrospective single-center analysis	
F. Eichhorn, L.V. Klotz, T. Muley, S. Kobinger, H. Winter, M.E. Eichhorn (Germany)	95
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile	
B.C.M. Hermans, J.L. Derks, E. Thunnissen, R.J. van Suylen, M.A. den Bakker, H.J.M. Groen, E.F. Smit, R.A. Damhuis, E.C. van den Broek, A. Ruland, E.J.M. Speel, A.M.C. Dingemans (The Netherlands)	102
Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer	
J. Bar, E. Ofek, I. Barshack, T. Gottfried, O. Zadok, I. Kamer, D. Urban, M. Perelman, A. Onn (Israel)	109
Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease	
N. Zhou, Y. Lin, X. Peng, Y. Wang, Y. Wang (China)	116
A phase 2 study of lenvatinib in patients with <i>RET</i> fusion-positive lung adenocarcinoma	
T. Hida (Japan), V. Velcheti, K.L. Reckamp (USA), H. Nokihara (Japan), P. Sachdev (USA), T. Kubota, T. Nakada (Japan), C.E. Dutcus, M. Ren (USA), T. Tamura (Japan)	124
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors	
J. Subramanian, A.W. Fernandes (United States), F. Laliberté (Canada), M. Pavilack, M. DerSarkissian, M.S. Duh (United States)	131
<i>Correspondence</i>	
Optimization of response classification criteria for patients with malignant pleural mesothelioma, a validation study	
W.A. Buikhuisen (the Netherlands), F. Qayyum, S.G. Armato III (USA), P. Baas (the Netherlands)	139
<i>Errata</i>	
Erratum to “Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib” [Lung Cancer, 108 (June 2017) 228-231]	
S.-H.I. Ou, J. Cui, A.B. Schrock, M.E. Goldberg, V.W. Zhu, L. Albacker, P.J. Stephens, V.A. Miller, S.M. Ali (USA)	141
Erratum to “Somatic mutation of LRP1B is associated with tumor mutational burden in patients with lung cancer” [Lung Cancer 132 (June) (2019) 154-156]	
S. Lan, H. Li, Y. Liu, L. Ma, X. Liu, Y. Liu, S. Yan, Y. Cheng (China)	142